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Abstract
Recent advances in genetic engineering are bringing
new promise for controlling mosquito populations
that transmit deadly pathogens. Here we discuss past
and current efforts to engineer mosquito strains that
are refractory to disease transmission or are suitable
for suppressing wild disease-transmitting populations.
Introduction
Mosquitoes transmit a variety of infectious agents that
are a scourge on humanity. Malaria, dengue fever, yellow
fever, and other mosquito-borne infectious diseases infect
millions of people and account for hundreds of thousands
of deaths each year, posing a huge burden for public
health and on the economic growth of countries where
these diseases are endemic [1]. Given the lack of effective
vaccines against many mosquito-borne pathogens,
national programs are heavily reliant on the use of
insecticides to control mosquito populations in order
to stop disease transmission [2]. Unfortunately, the
alarming pace of emergence of insecticide resistance in
mosquitoes [3] is threatening chemical-based campaigns
and is forcing scientists to develop alternative strategies
to combat vector-borne diseases. Moreover, insecticide-
treated bed nets and indoor residual sprays principally
target mosquitoes that feed indoors at night and that rest
inside houses, thereby neglecting those species that prefer
to bite and rest outdoors or at earlier hours of the day, and
inducing some degree of insecticide-avoidance behavior
(behavioral resistance) in indoor-biting individuals [4-6].
Recent major advances in the field of genetic engineering
are providing an unprecedented opportunity to conceive
and create designer mosquito strains in order to control
natural vector populations. From the generation of the first
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transgenic mosquitoes [7-10] to the creation of the first
gene knock-outs [11-13], the discovery of genetic tools has
revolutionized our ability to functionally study and edit the
mosquito genome. In the fight against infectious diseases,
vector populations can be modified using these tools in
two principal ways: 1) they can be made refractory to
disease transmission by the introduction of genes with
anti-pathogenic properties; 2) they can be rendered
sterile or modified in such ways that the population
size will crash below the threshold necessary to support
disease transmission (Figure 1) [14]. Both strategies have
strengths and limitations that are inherent to their design
and properties.
Genetic engineering technologies include those that
allow heterologous gene expression and those that modify
endogenous genes or entire portions of the mosquito
g e n o m e .H e r ew er e v i e wt h eg e n e t i ct o o l st h a ta r ec u r r e n t l y
in use and those that promise to become available in the
near future, with particular focus on those techniques that
are capable of reprogramming the genomes of field
populations. We also discuss current field trials in which
genetically modified mosquitoes are being released, and will
mention ecological hurdles and potential environmental
and regulatory issues stemming from the release of
genetically modified insects into the wild.
First generation of anti-pathogenic strains
The expression of exogenous genes - through the
transposon-mediated integration of transgenes - was the
first genomic technology to be developed in mosquitoes,
and gave birth to the modern field of mosquito genome
engineering [7-10]. In this initial system, different exogen-
ous ‘effector’ genetic elements are cloned between the
transposon terminal repeats (usually using the PiggyBac
transposon [10]) to form a synthetic element that, in the
presence of the integrating enzyme transposase, inserts into
the mosquito genome at quasi-random loci (Figure 2a). In
order to identify successful transformants, synthetic
transposons are generally designed to carry a fluorescent
reporter construct, such as the green fluorescent protein
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http://genomebiology.com/2014/15/11/535(GFP), that acts as a selectable marker [18]. The promoter
of choice for the expression of selectable markers is often
the neuronal 3xP3 promoter [19], which is expressed
during larval development allowing easy detection of
fluorescence and facilitating high-throughput sorting
by automated live sorters [20]. Moreover, this system can
incorporate cargoes with anti-pathogenic properties to
render mosquitoes refractory to disease transmission.
Both Anopheles and Aedes mosquito species, the vectors
of malaria and dengue, respectively, have been modified to
reduce their vectorial capacity. To stop the development
of Plasmodium parasites, the causative agents of malaria,
scientists have developed transgenic Anopheles stephensi
lines that express single chain variable fragment antibodies
(scFvs) [21-23] or synthetic antimalarial factors [24,25]
(Figure 2b). Transgenic lines that express ScFvs against
the ookinete proteins Chitinase 1 and Pfs25 [38,39]
o rt h ep r e d o m i n a n ts u r f a c ep r o t e i no ft h es p o r o z o i t e s ,
circumsporozoite protein [40,41], show reduced ookinete
crossing of midgut walls or sporozoite invasion of the
salivary glands, respectively. Similarly, An. stephensi
strains have been generated that secrete the synthetic
dodecapeptide SM1 (an acronym for salivary gland- and
midgut-binding peptide 1) into the midgut lumen during
blood feeding. SM1 binding to the epithelium - probably
through a mosquito midgut receptor - prevents ookinetes
from invading the midgut in the rodent malaria
Plasmodium berghei model, thereby reducing both
the prevalence and the intensity of infection [24].
Additionally, the incorporation of bee venom phospholip-
ase A2 into transgenic An. stephensi inhibits ookinete inva-
sion of the midgut by modifying epithelial membranes [25].
Anopheles gambiae, the principal vector of malaria in
sub-Saharan Africa, has been engineered to ectopically
express the endogenous antimicrobial peptide cecropin A
[26] and the synthetic peptide Vida3 [27], a hybrid
peptide based on natural antimicrobial peptide sequences
that have strong activity against Plasmodium sporogonic
forms [28].
Different laboratories have also developed Anopheles
strains modified in key endogenous cellular pathways that
regulate parasite development, namely the insulin-growth
factor signaling (ISS) and the immune deficiency (IMD)
pathways. In An. stephensi, overexpression of Akt, a
critical regulator of ISS, elicits mitochondrial dysfunction
that enhances parasite killing in the midgut, even if at
some cost to mosquito survival [42,43]. To overcome
fitness costs, an inhibitor of ISS, the phosphatase and
tensin homolog (PTEN), was instead overexpressed [44].
PTEN inhibits phosphorylation of the ISS protein FOXO,
and its expression blocks Plasmodium development by
enhancing the integrity of the midgut barrier, although
this causes an increase in the female lifespan with possible
negative consequences for disease transmission [44]. In
another study, An. stephensi mosquitoes were engineered
to express the active form of the IMD-regulated NF-κB
transcription factor Rel2-S. Rel2-S activates the expression
of several antimicrobial and anti-Plasmodium peptides,
and when overexpressed in the midgut and in the fat body,
it strongly inhibits parasite development [45].
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Figure 1 Methods for the genetic control of vector populations.
(a) Population suppression can be achieved by releasing large
numbers of males that render their wild female mates incapable of
having viable progeny. This includes releasing either males that are
sterile and produce no progeny at all (as in sterile insect technique
(SIT)) [15] or males that pass on lethal transgenes to the next
generation, producing progeny that die before they can transmit
disease (as in the release of insects carrying dominant lethals, RIDL)
[16]. For SIT strategies, multiple releases of a large excess (5x to 10x) of
sterile males relative to the target population are normally carried out
over large areas. (b) Population replacement occurs when traits carried
by a small number of engineered mosquitoes replace traits that
naturally exist in field populations [17]. The desired engineered
trait - for instance, an anti-pathogen gene that renders mosquitoes
refractory to disease transmission - is driven to fixation in the field
population using a genetic drive (as described in Figure 2h).
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to anophelines. Dengue virus infections in Aedes aegypti
mosquitoes have been attenuated by exploiting the
natural antiviral RNA interference pathway. An inverted-
repeat RNA capable of forming double-stranded RNAs
that target the pre-membrane protein coding region of the
DENV-2 serotype was expressed in the midgut [29] or in
the salivary glands [30]. This modification reduced viral
titers by more than five-fold compared to those in control
mosquitoes. It should be noted, however, that multiple
dengue serotypes (as well as multiple human malaria para-
sites) exist, complicating population replacement efforts
aimed at spreading pathogen-refractory genes into wild
populations.
First generation of sterile strains for population
suppression
Early transposon-based technology has been also used to
generate mosquito strains aimed at the suppression or
elimination of vector populations through the release of
sterile males (the sterile insect technique (SIT)) [15].
The alternative sister strategy is the release of insects
carrying a dominant lethal (RIDL) modification [16]. SIT
is based on the release of large numbers of sterile males,
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Figure 2 Current and future genetic engineering technologies for vector control. (a) First-generation technologies make use of transposable
elements to insert genetic cargo randomly into the genome. The transposable element is mobilized by a transposase enzyme produced by another
plasmid, which recognizes and cleaves the terminal repeats (TR) of the transposon cassette and mediates insertion of the transposable element into
the genome. Insertion is visualized using selectable markers such as the green fluorescent protein (GFP) [19]. (b) Mosquitoes can be engineered to
carry anti-pathogenic effector genes that reduce the pathogen load [21-31]. In the figure, the effector gene blocks Plasmodium ookinete invasion of
the midgut epithelium, preventing oocyst development. (c) Schematic of the RIDL system currently used for suppression of Aedes aegypti populations
[16]. In the presence of tetracycline, expression of the tetracycline transactivator (tTA) is repressed. In the absence of tetracycline, tTA binds tot h e
tetracycline-responsive element (tRE) and drives its own expression in a positive feedback loop that leads to the accumulation of toxic levels of tTA.
The progeny of released males carrying this transgene are not viable. Other combinations of inducible systems and toxic genes can be used in place
of tTA and tRE to achieve population suppression. (d) Second generation technologies include HEGs, ZFNs, TALENs and CRISPR/Cas9 [11-13,32,33].
These technologies facilitate double-stranded DNA breaks in the genome at desired loci. (e) HEGs, TALENs and ZFNs have been used in Ae. aegypti
and Anopheles gambiae to generate null mutants [11-13], including eye color mutants [11]. (f) ZFNs have been used to generate site-specific knock-ins
of exogenous sequences in Ae. aegypti [34]. The figure illustrates a possible application for knock-in technology, which would enable scientists to fuse
protein domains to the end of endogenous genes. These domains include those encoding fluorescent proteins or epitope tags, such as an HA tag
(shown). (g) Sex distorter strains make use of an HEG, I-PpoI, to destroy sperm carrying an X chromosome (X-shredder), producing male-only
populations. When mated to wild-type females, transgenic males sire only sons, potentially leading to population suppression [35]. (h) Gene drives are
genetic elements that are inherited in a non-Mendelian fashion and can spread through populations. Gene drives using HEGs have been successfully
developed to drive through laboratory mosquito populations [36], whereas evolutionarily stable drives enabled by CRISPR/Cas9 have been
proposed [37].
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sterilants, that upon mating with field females produce no
fertile progeny causing suppression or elimination of local
populations (Figure 1a) [15]. The sterilization process
usually induces severe fitness costs in the male, such that
larger numbers of males than those initially predicted by
simple models need to be released to achieve the desired
level of suppression [46]. Genetic engineering can not only
enable high-throughput sorting of male-only populations
based on sex-specific fluorescent markers [47,48], but
can also enable the design of strains in which specific
sterility-inducing transgenes or genetic mutations have been
introduced without causing the fitness costs associated with
irradiation [49,50]. The most successful RIDL example is
provided by the Ae. aegypti strain OX513A [16], which
carries an inducible dominant genetic system that kills late
larval stages. This system is composed of a gene encoding
the tetracycline transactivator (tTA) protein under the
control of the tetracycline-responsive element (tRE).
Binding of tetracycline to tTA prevents tTA from activating
transcription; when tetracycline is removed, tTA instead
binds to tRE, thereby inducing its own expression via a
positive feedback loop. The accumulation of tTA is toxic to
cells and ultimately leads to organismal death (Figure 2c).
This repressible system allows the generation of males that
are fertile in the laboratory but that, once released, sire
unviable progeny upon mating with field females. These
RIDL strains are already being released in different
geographical locations as part of field trials.
A different approach, initially developed in Ae. aegypti
and now transferred to Aedes albopictus and An. stephensi,
is based on a bimodular system that severely impairs the
functionality of the female flight muscles, disrupting the
female’s ability to fly (fsRIDL) [51-53]. The first module
consists of tTA under the control of the female-specific
Actin-4 transcriptional regulatory elements, which drive
gene expression in the indirect flight muscles of
female pupae. The second module comprises a lethal
gene (Nipp1Dm or michelob_x in Ae. aegypti, VP16 in
Ae. albopictus and Nipp1Dm in An. stephensi) under the
control of tRE. In the absence of tetracycline, expression
o ft h el e t h a lg e n es p e c i f i c a l l yi nt h ef e m a l ef l i g h t
muscles causes cell death and inability to fly. As
males are unaffected by the transgene, their release
will generate flightless female progeny that are unable
to mate, bite, and transmit disease, eventually leading
to population suppression [51].
Second generation transgenesis provides
increased flexibility
New genome-editing tools now allow scientists to modify
endogenous genes with increasing flexibility and ease,
and are being utilized in the laboratory with promising
results to reduce the vectorial capacity of mosquito vectors
(Figure 2d). The flexibility of these tools resides in the use
of protein precursors that can be designed to bind
sequences of interest within the mosquito genome [11-13].
Repetitive zinc finger (ZF) and transcription activator-like
effector (TALE) modules have been successfully fused to
the endonucleolytic domains of a type II endonuclease,
normally FokI, to generate knock-out and knock-in
mutants [11-13,34] (Figure 2e,f). These modified nucleases
cause site-specific double-stranded DNA breaks that can
be repaired by the non-homologous end-joining (NHEJ)
pathway, an error-prone repair pathway that often
results in small indels. As a basic proof-of-principle,
this technology has been used to generate eye-color
mutants (Figure 2e) [11], but it can also help elucidate
pathways that are important for vector competence.
For example, TALE nucleases (TALENs) have been
used in An. gambiae to generate null mutants of the
thioester-containing protein 1 (TEP1) gene, a complement-
like factor that opsonizes Plasmodium parasites in the
midgut and mediates their killing. Mutant strains are,
therefore, hyper-susceptible to Plasmodium infection [13],
and although not directly employable for malaria control,
they allow detailed genetic analyses of anti-Plasmodium
immune pathways. Similarly, the zinc-finger nuclease
(ZFN)-mediated knock-out of the odorant receptor co-
receptor (ORCO) in Ae. aegypti has enabled the analysis
of pathways involved in host-seeking behavior for blood
feeding [12], opening up new avenues for the development
of mosquito repellents and attractants. In another study,
the CO2 response of Ae. aegypti mosquitoes was analyzed
in mutants that have a defect in the AaegGr3 gene, which
encodes a subunit of the heteromeric CO2 receptor,
contributing to our understanding of mosquito attraction
to humans [34]. This mutant, the first knock-in to be
reported in mosquitoes, was generated by the disruptive
insertion of a fluorescent reporter gene into the AeagGr3
locus. Such knock-in technology could also be used to
facilitate in-frame insertions of protein tags into genes of
interest, further enabling the study of complex pathways
in mosquitoes (Figure 2f).
Homing endonucleases (HEGs) have also been success-
fully used to manipulate the mosquito genome [32,54,55].
HEGs are double-stranded DNases targeting large (12 to
40 bp) asymmetric recognition sites that occur extremely
rarely in genomes [56]. An. gambiae strains have been
generated that express I-PpoI, a HEG that recognizes and
cuts a site in a multi-copy rDNA gene, which in this
species is located exclusively on the X chromosome
[35,57]. When I-PpoI is expressed specifically during
spermatogenesis, it cleaves these multiple target sequences
causing shredding of the paternal X chromosomes in sperm
cells [35,57]. This feature was originally meant to generate
male-only populations by preventing fathers from transmit-
ting the X chromosome to embryos; but I-PpoIe x p r e s s i o n
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probably as a consequence of the shredding of the
maternal X chromosome upon unintended transfer of
the enzyme to the embryo [57]. These strains induce
a high level of infertility in large cage trials, as discussed
below [58]. An improved version of these strains, which
carries a less thermostable version of I-PpoI with reduced
in vivo half life, has been generated that is instead active
only in the testes, causing the specific shredding of
the paternal X chromosome in sperm without directly
affecting the embryo [35] (Figure 2g). The resulting
sex-distorter strains produce >95% male offspring and
are able to suppress wild-type mosquito populations
in laboratory cages [35].
Gene drives for population replacement
For the implementation of population replacement
strategies aimed at curbing mosquito-borne diseases,
the anti-pathogen constructs described above need to
be driven genetically through natural populations so that
the disease refractory traits will spread (Figure 2h). A
number of artificial gene-drive systems capable of forcing
their own spread in a non-Mendelian manner are being
developed that could be used for this purpose. In the
model organism Drosophila melanogaster,t h ef i r s t
gene-drive mechanism was developed on the basis of
a toxin-antidote system [59]. This synthetic system,
named Medea after the mythological figure of the
woman who killed her own children to take revenge
on her husband’s betrayal, is based on expression in
the zygote of a toxic gene, such as a microRNA
against a maternal mRNA essential for embryonic
development [59,60]. Transgenic females carry an
‘antidote’, that is, an allele of the gene that is insensitive to
the toxin, allowing transgenic progeny to survive and
spread the transgene. Although Medea has yet to be
adapted to disease vectors, HEG-based technologies have
been suggested and tested as gene drives in mosquitoes
[36,61]. In this system, the drive encodes DNA-cutting
machinery that cleaves a wild-type target locus from a
transgene located at the homologous locus. Repair of the
DNA break by homologous recombination causes the
transgene to copy into the cleaved locus, causing a
hemizygous cell to become homozygous for the transgene
(Figure 2h). If this mechanism occurs in the germline,
the transgene can spread through the population,
potentially carrying an anti-pathogenic construct with it.
Proof-of-principle use of HEGs to facilitate gene-drive
mechanisms in An. gambiae was based on the I-SceI
enzyme, which targeted its own recognition sequence that
had been artificially introduced into a GFP reporter
gene [36]. Homing of the HEG into its target sequence, pre-
viously integrated into the mosquito genome, would there-
fore generate GFP null mutants. Small cage experiments
indicated that I-SceI could rapidly invade the receptive
target strain, providing the first evidence of the gene-drive
capabilities of HEGs in mosquitoes [36].
The range of applications enabled by HEGs and other
nuclease-based technologies (ZFNs and TALENs) has some
limitations, especially in terms of specificity, flexibility and
stability. For example, ZFNs do not always have the desired
sequence specificity when assembled into arrays, which
limits the number of loci that can be targeted [62]. HEGs
have been shown to cleave non-target sites (for a review
see [63]), and laborious in vitro studies are necessary to
generate new enzymes that have the required sequence
specificity [64]. Furthermore, as these systems cut a single
genomic sequence at a time, new transgenic strains must
be created for each target sequence. A new genome-
engineering tool, CRISPR/Cas9 (for clustered regularly
interspaced short palindromic repeats/CRISPR-associated
protein 9), has the potential to overcome these limitations
and stimulate the generation of effective gene drives for
vector control. Discovered as the molecular machinery of a
bacterial acquired immune defense system [65], CRISPR/
Cas9 was soon co-opted to engineer the genomes of a wide
variety of organisms with high flexibility and efficiency [33].
Cas9 is an endonucleolytic protein that can recognize and
cleave specific genomic sequences with the help of a
small artificial guide RNA (gRNA). When the gRNA
and Cas9 form a complex, they catalyze DNA cleavage
upon recognition of the target site by the gRNA. The
reliance on easily designed gRNAs for the recognition of
target sequences results in a significant increase in the
number of genomic loci that can be cleaved when
compared to other systems, as RNA-guided engineering
does not require modification of the Cas9 protein
itself. Moreover, a number of loci can be targeted
simultaneously by providing multiple gRNAs, thereby
reducing the possible emergence of resistance to cleavage
[37]. Although research demonstrating the use of CRISPR/
Cas9 in mosquitoes has yet to be published, it is likely that
this technology will soon enable the development of
innovative and evolutionarily stable gene drives for
the control of vector-borne diseases. Nevertheless, further
research is needed to demonstrate the improved perform-
ance of this system over already existing technology,
including minimizing off-target cleavage events and the
possibility to revert the effects of the introduced gene
architectures [37].
Current field trials utilizing genetically modified
mosquitoes to fight disease
Intensive research is ongoing to generate improved
engineered strains that are suitable for vector-control
programs, but the first generation of genetically modified
mosquitoes is already being released in the field. Since
2009, the UK-based biotech company Oxitec has been
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the first releases of transgenic Ae. aegypti RIDL strains to
suppress wild populations [66-69]. Their aim is to test the
efficacy of these strains as a tool against dengue, a viral
disease for which no vaccine or effective drugs are available.
Repeated releases of the RIDL strain OX513A achieved a
sizable reduction of wild populations, bringing new promise
for disease control. The first program was operated on
Grand Cayman Island, a British Territory in the Caribbean
[66]. An average of 465 males/hectare (ha)/week were
released across 10 hectares over a 4-week period,
representing about 16% of the male population in the
field. A total of 9.6% of fluorescent larvae were detected
from eggs collected in ovitraps three weeks after the
release, demonstrating that RIDL males could mate with
wild females and sire progeny, despite their reduced field
competitiveness. A subsequent program, using 3,500
males/ha/week, was carried out over a 23-week period
and achieved 80% suppression of the wild population
in a 16-ha area [67]. To accomplish this task, 3.3 million
engineered males were reared and released, stressing the
need to optimize mass-rearing protocols [69]. OX513A
was also released in a forested area in Pahang, Malaysia,
and transgenic males were shown to live as long as their
wild-type brothers from the same laboratory strain, even if
their dispersal ability was reduced [68]. Releases of
OX513A are currently being performed in Brazil [69],
where additional trials are planned and the mosquito
production factory is being expanded. Large outdoor field
cages have also been employed to test the potential use of
the flightless Ae. aegypti fsRIDL strain [51,70]. This strain
did not, however, achieve complete suppression of target
populations, suggesting that it may not be suitable for
large-scale releases [70]. Reduced mating competitiveness
of transgenic males probably contributed to test failure
but other explanations, including the different genetic
backgrounds of released individuals and wild populations,
have also been proposed [70].
In the case of malaria vectors, large caged laboratory trials
have been established to test the mating competiveness of
sterile An. gambiae males carrying the HEG I-PpoI. When
released at 5- to 10-fold coverage in large cages, I-PpoI
males induced high levels of infertility, leading to the
suppression of caged populations in 4 to 5 weeks,
despite showing reduced mating competitiveness [58].
Males carrying a less thermostable version of I-PpoI, which
causes sex distortion rather than male infertility, also
achieved elimination of caged populations within six
generations when released at a 3x ratio [35]. Before
the field release of these strains is contemplated, their
competitive performance and sterilizing activity will
need to be tested in semi-field settings, such as those
provided by large outdoor enclosures, where mosqui-
toes are exposed to normal environmental conditions
and must produce appropriate swarming and mating
behavior [71].
Ecological hurdles and environmental and
regulatory considerations
The implementation of genetically modified mosquitoes
in vector control programs is challenged by a number
of ecological, environmental and regulatory issues
(summarized in Figure 3). Two crucial behavioral
components of the released males are dispersal ability,
which affects the possibility of targeting populations
in impenetrable regions [68], and mating competitiveness,
especially for species with complex sexual behaviors [72].
Indeed, the mating fitness of released males has proven to
be an important limiting factor in previous campaigns
aimed at reducing the size of Anopheles populations (for a
comprehensive discussion of these issues see [73] and
references therein). Generally, anopheline species mate in
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Figure 3 Challenges for the field release of transgenic
mosquitoes. This scheme summarizes the ecological, behavioral and
regulatory issues faced by disease control programs based on the
release of genetically modified mosquitoes. Ecological requirements
are shown in green, behavioral requirements in orange, while
regulatory issues are presented in blue. Light-grey sections highlight
operational tools that may be used to comply with the requirements.
Behavioral requirements include key fitness parameters such as the
dispersal ability and mating competitiveness of released males, and
can be tested in large laboratory cage trials and then in semi-field
settings to select the mosquito strains with the greatest probability of
success. Ecological hurdles comprise heterogeneity in the genetics,
behavior and natural habitats of vector species (biodiversity), and
possible unintended side-effects on non-target species or on the
ecosystem. Monitoring of these effects must be constantly in progress
in the release phase. The risks, safety and specificity of the engineered
strains need to be evaluated by appropriate regulatory agencies, and
early public engagement is a priority.
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and in which males are subject to strong competition to
find a mate [74]. Reduction of competitiveness can be
caused by a number of factors including but not limited to
mass rearing, inbreeding, transposon expression and
insertion sites in the genome [75-77]. The latter issue can
now be partially overcome by utilizing ‘docking’ strains
that are selected on the basis of limited fitness costs, using
the PhiC31 integration system [78].
Other ecological features, including the biodiversity of
native vector species, will also determine the success of
a release campaign (Figure 3). Malaria transmission is
supported by over 30 major primary vectors [79], many
of which are morphologically indistinguishable [80].
These often sympatric species exhibit distinct behaviors in
terms of mating, blood feeding and resting, and inhabit
diverse ecological niches, making their control extremely
arduous [81]. Such complexity represents a significant
hurdle to the implementation of genetic engineering for
malaria control; elimination of this disease solely by
transgenic means would require the simultaneous
release of all malaria-transmitting species in any given
area, a highly arduous task. By contrast, dengue virus
infections are transmitted worldwide principally by
Ae. aegypti and few other Aedes species. Although genetic
variations between different Ae. aegypti populations have
been detected [82], pilot RIDL anti-dengue campaigns
suggest that a single transgenic strain can adapt to differ-
ent ecological contexts [67-69]. The same strain could
potentially be deployed to reduce the spread of the other
viral diseases transmitted by these mosquitoes, such as
yellow fever and Chikungunya, the latter being an emerging
threat in the Americas [83].
Finally, although the scope of this review is to describe
the state of the art in transgenic technologies for disease
control, we should mention that the release of genetically
modified mosquitoes generates environmental and safety
challenges that deserve to be meticulously addressed in
each individual case (outlined in Figure 3). Unintended
ecological side effects, accidental spread to non-target
species, and horizontal transfer of the transgenes are
all unlikely but possible negative scenarios that can
and must be safely minimized [84]. Test trials under
high containment levels and in confined laboratory
and semi-field settings should be used to determine
specificity and safety of modified vectors, and constant
monitoring should occur during the release phase. This is
especially important when releasing gene-drive architec-
tures that are capable of spreading through entire popula-
tions, such as those afforded by meiotic drives, HEGs and
CRISPRs. The fast and exciting pace of progress provided
by genetic-engineering techno l o g i e sr e q u i r e sa no p e na n d
early discussion to engage regulatory agencies, the scientific
community, and the public [85]. The end goal of genetic
engineering for mosquito control is to provide future gener-
ations with the undisputable benefits of a world free of
vector-borne pathogens, while ensuring that possible
unanticipated ecological and environmental consequences
are eliminated.
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